Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. develops thrombectomy technologies for medical conditions involving blood clots, including ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its product portfolio includes computer assisted vacuum thrombectomy and devices such as the Indigo System, Penumbra System Reperfusion Catheter, ACE Reperfusion Catheters, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and Artemis Neuro Evacuation Device.
Recurring company news covers financial results, capital-structure updates, investor conference presentations, and clinical evidence for CAVT in pulmonary embolism and other vascular applications. Updates also include material agreements, shareholder voting matters, governance disclosures, and regulatory or clinical developments tied to Penumbra's thrombectomy and neurovascular products.
Penumbra, Inc. (NYSE: PEN) has scheduled a conference call on November 3, 2022, at 4:30 PM ET to discuss its third quarter 2022 financial results. The earnings release will be made available after market close on the same day. Interested parties can access the call by dialing (888) 330-2443 or via the webcast on the company's website. Penumbra focuses on innovative therapies and has a significant presence in over 100 countries, supporting healthcare providers with its broad product portfolio.
Penumbra, Inc. (NYSE: PEN) has announced a collaboration with Asahi Intecc Co. to introduce the Indigo™ Aspiration System in Japan after gaining regulatory approval. This advanced peripheral mechanical thrombectomy technology targets blood clot removal in arterial and venous systems, addressing conditions like acute limb ischemia and pulmonary embolism. The system features cutting-edge Lightning technology, designed to differentiate between clot and blood, minimizing blood loss during procedures. This partnership aims to enhance patient care and meet the increasing medical needs in Japan.
Penumbra, Inc. (NYSE: PEN) announced the European launch of its RED® Reperfusion Catheters following CE Mark approval. These catheters, part of the Penumbra System®, are designed for mechanical thrombectomy in acute ischemic stroke patients. Initial data from the INSIGHT Registry revealed a 68.9% first-pass revascularization success rate across all clot types. The RED catheters feature advanced trackability and aspiration technologies, enhancing their effectiveness. This expansion aims to improve treatment options for stroke patients in Europe, enabling faster and more efficient clot removal.
Penumbra, Inc. (NYSE: PEN) announced promising results from its initial INSIGHT Registry data, revealing that its RED® reperfusion catheters achieved a first-pass revascularization rate of 68.9% in acute ischemic stroke patients. Additionally, findings from the COMPLETE study indicate that the Penumbra System effectively treats patients with tandem lesions and those in the late treatment window, with successful revascularization rates of 89% for tandem lesions and 83.2% for late window patients. These data were presented at the 2022 WFITN conference in Kyoto, Japan.
Penumbra, Inc. (NYSE: PEN), located in Alameda, California, has announced participation in two upcoming investor conferences. The company will present at the 2022 Wells Fargo Securities Healthcare Conference on September 7, 2022, at 9:45 AM ET and at the Morgan Stanley Global Healthcare Conference on September 13, 2022, at 12:20 PM ET. Webcasts will be available on their investor website for two weeks following the events.
Penumbra, Inc. (NYSE: PEN) reported Q2 2022 revenue of $208.3 million, marking a 13.1% increase from Q2 2021. Revenue growth was strong in vascular products, up 22.7% to $123.5 million, while neuro products grew 1.5% to $84.8 million. Gross profit was $134.0 million with a margin of 64.3%. However, total operating expenses rose significantly to $134.2 million, impacting profitability. The company maintains its full-year revenue guidance of $860 million to $875 million, expecting growth of 15-17% on a constant currency basis.
Penumbra, Inc. (NYSE: PEN) will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 8:30am ET. The event will be held in Alameda, California.
A webcast of the presentation will be accessible on the company's investor website for at least two weeks after the event. Penumbra is dedicated to innovative healthcare solutions, operating in over 100 countries.
Penumbra, Inc. (NYSE: PEN) will host a conference call to discuss its second quarter 2022 financial results on August 4, 2022, at 4:30 PM Eastern Time. The results will be released after market close on the same day. The conference call can be accessed via phone or through a webcast available on the company's website. Penumbra focuses on innovative therapies to meet significant unmet medical needs, supporting healthcare providers in over 100 countries.
Penumbras, Inc. (NYSE: PEN) reported Q1 2022 revenues of $203.9 million, reflecting a 20.5% increase from Q1 2021. Vascular product sales surged 37.7% to $122.8 million, while neuro product revenues grew modestly by 1.3% to $81.1 million. Despite revenue growth, the gross profit decreased to 62.5% of total revenue, down from 65.8% a year ago, impacted by rising labor and logistics costs. Operating expenses increased substantially to $131.5 million, resulting in an operating loss of $4.0 million for the quarter.
Penumbra, Inc. (NYSE: PEN) will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 4:40 PM PT / 7:40 PM ET. The event will provide insights into the company's innovative healthcare solutions and strategies. A webcast of the presentation will be available on Penumbra's website for two weeks post-event. Headquartered in Alameda, California, Penumbra designs and markets therapies addressing significant medical needs globally.